中药口服液联合阿奇霉素治疗儿童支原体肺炎的贝叶斯网络Meta分析
该贝叶斯网络Meta分析纳入63项RCT共6410例儿童,评价5种中药口服液联合阿奇霉素治疗支原体肺炎的疗效与安全性。结果显示联合治疗主要结局优于单用阿奇霉素,小儿消积止咳联合阿奇霉素在有效率与肺部啰音消失时间上表现最佳,不良反应差异无统计学意义,但证据确定性低。
要点
- 中药口服液联合阿奇霉素较单用阿奇霉素改善儿童支原体肺炎主要结局。
- 小儿消积止咳联合方案在有效率和肺部啰音消失时间上排名最高。
- 不良反应与单用阿奇霉素差异无统计学意义,但安全性证据不足。
核心结论
- 中药口服液联合阿奇霉素治疗儿童支原体肺炎的主要结局优于单用阿奇霉素。
- 小儿消积止咳可能是联合阿奇霉素治疗儿童支原体肺炎的最佳选择。
- 因证据确定性低,结果需谨慎解读,中药口服液安全性尚不明确。
研究设计与样本
- 贝叶斯网络Meta分析,检索PubMed、Embase、Cochrane Library、Ovid、Web of Science、CNKI、万方、维普数据库。
- 纳入数据库建库至2020年10月发表的随机对照试验(RCT),共63项RCT、6410例儿童。
- 采用贝叶斯随机效应模型和累积排序曲线下面积(SUCRA)评分排序,并用GRADE评级证据确定性。
主要发现
- 共5种中药口服液联合阿奇霉素的方案被纳入分析。
- 小儿消积止咳联合阿奇霉素的有效率OR=6.5(95%CrI 4.3-10,低确定性),SUCRA 85%。
- 小儿消积止咳联合阿奇霉素的肺部啰音消失时间MD=-2.1(95%CrI -2.9至-1.2,低确定性),SUCRA 80%。
- 蒲地蓝消炎联合阿奇霉素的咳嗽消失时间MD=-2.6(95%CrI -3.4至-1.7,极低确定性),SUCRA 87%。
- 蒲地蓝消炎联合阿奇霉素的退热时间MD=-1.8(95%CrI -2.3至-1.3,极低确定性),SUCRA 87%。
关键数值与推荐
- 小儿消积止咳联合阿奇霉素的有效率OR=6.5(95%CrI 4.3-10,低确定性)。
- 小儿消积止咳联合阿奇霉素的肺部啰音消失时间MD=-2.1(95%CrI -2.9至-1.2,低确定性)。
- 蒲地蓝消炎联合阿奇霉素的咳嗽消失时间MD=-2.6(95%CrI -3.4至-1.7,极低确定性)。
- 蒲地蓝消炎联合阿奇霉素的退热时间MD=-1.8(95%CrI -2.3至-1.3,极低确定性)。
临床怎么用
- 儿童支原体肺炎可考虑中药口服液联合阿奇霉素以改善主要结局。
- 若以有效率和肺部啰音消失为优先,可参考选用小儿消积止咳联合方案。
- 若以咳嗽和退热时间为优先,可参考选用蒲地蓝消炎联合方案。
- 联合用药时需关注中药口服液安全性,目前证据尚不明确。
局限性
- 纳入研究的证据确定性低至极低,结论需谨慎解读。
- 中药口服液的安全性因证据缺乏尚不明确。
- 需要更多高质量RCT进一步评估这些中药口服液的疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Mycoplasma pneumoniae pneumonia (MPP) causes flu-like symptoms in children, increasing the burden on the health and education systems. In China, traditional Chinese medicine oral liquids (TCMOLs) combined with azithromycin (TCMOLs + Azithromycin) is commonly used to treat MPP in children. However, TCMOLs with the optimal clinical applicability remain unknown. Here, we evaluated the clinical effectiveness and safety of TCMOLs + Azithromycin in children with MPP. Methods: We searched PubMed, Embase, Cochrane Library, Ovid, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, and VIP information resource integration service platform databases for eligible randomized controlled trials (RCTs) published from database inception to October 2020. Two reviewers independently performed data extraction and risk of bias assessment. After Bayesian random effect modeling and surface under the cumulative ranking curve (SUCRA) scoring, we ranked each intervention. We assessed heterogeneity using multivariate meta-regression for potential modifiers and used the Grading of Recommendations, Assessment, Development, and Evaluation to rate pooled evidence's certainty. Results: In the 63 included RCTs with 6,410 children, five different TCMOLs were combined with azithromycin. TCMOLs + Azithromycin had significantly better primary outcomes than did azithromycin alone. Of all TCMOLs, Xiaoer Xiaoji Zhike (XEXJZK)+Azithromycin showed the best effectiveness with respect to the response rate (odds ratio [OR] = 6.5, 95% credible interval [CrI] = 4.3-10; low certainty) and pulmonary rales disappearance time (mean difference [MD] = -2.1, 95% CrI: -2.9 to -1.2; low certainty) with SUCRA 85 and 80%, respectively. Pudilan Xiaoyan + Azithromycin showed the highest effectiveness with respect to cough disappearance time (MD = -2.6, 95% CrI: -3.4 to -1.7; very low certainty) and fever disappearance time (MD = -1.8, 95% CrI: -2.3 to -1.3; very low certainty) with SUCRA 87 and 87%, respectively. The difference in the adverse effects between TCMOLs + Azithromycin and azithromycin alone was nonsignificant. Conclusion: Of the different TCMOLs, XEXJZK may be the best option to combine with azithromycin to treat children with MPP. However, our results should be interpreted with caution due to the low certainty of evidence. In general, TCMOLs' safety remains unclear because of a lack of evidence. More high-quality RCTs are needed to further evaluate efficacy and safety of these TCMOLs.
引用
- Chen Z, Shi Q, Peng Y, et al. Traditional Chinese Medicine Oral Liquids Combined With Azithromycin for Mycoplasma pneumoniae Pneumonia in Children: A Bayesian Network Meta-Analysis. Front Pharmacol. 2021. PMID: 34122075. doi:10.3389/fphar.2021.652412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。